Celyad Oncology Liabilities 2024

Celyad Oncology Aktienanalyse

What does Celyad Oncology do?

Celyad Oncology is a biotech company specializing in the discovery and development of new cancer immunotherapies. The company, headquartered in Mont-Saint-Guibert, Belgium, was founded in 2007 and has been listed on the NASDAQ and Euronext stock exchanges since September 2015. The history of Celyad Oncology began with the discovery of CAR-T therapy, which is based on the tumor cell recognition by T cells of the body's immune system. In 2001, researchers at the University of Leuven (Belgium) introduced a new method for culturing T cells, which was a major step in the development of CAR-T therapy. In 2004, the researchers founded Celyad with the aim of developing clinically effective CAR-T therapies. In 2015, the company was renamed Celyad Oncology to emphasize its strategic focus on oncology products. Celyad Oncology has developed a unique business model that focuses on the clinical development of CAR-T cell therapies. The company uses innovative technologies such as allogeneic CAR-T cells, which come from donor tissue from persons other than the patient. These cells have the advantage of being able to be produced in unlimited quantities, enabling the rapid and cost-effective manufacturing of CAR-T cells. In addition, the company has developed a platform technology called "shRNA" that regulates gene expression in T cells, thereby improving the safety and efficacy of CAR-T therapies. The company is divided into various divisions, from preclinical research to the clinical development and commercialization of CAR-T therapies. Celyad Oncology has several product candidates in various stages of development, focusing on indications such as multiple myeloma, acute myeloid leukemia (AML), and solid tumors. One of Celyad Oncology's most promising product candidates is CYAD-01, a CAR-T cell product targeting the CD19 protein. It is currently in a Phase I/IIa clinical trial evaluating the safety and efficacy of CYAD-01 in patients with refractory or relapsed CD19+ B-cell lymphoma. In October 2020, the product candidate achieved a complete response in a patient with a different indication, acute myeloid leukemia (AML). Another product candidate is CYAD-101, an allogeneic CAR-T cell product targeting the NKG2D protein. This protein is overexpressed on many cancer cells but not on healthy cells. CYAD-101 is currently in a Phase I/II clinical trial for the treatment of various tumor types, including lung cancer and pancreatic cancer. Celyad Oncology also collaborates with other companies to further develop its technologies and product candidates. In 2018, the company entered into a partnership with Novartis to utilize Celyad Oncology's CAR-T platform technology for the development of products for solid tumors. In 2019, Celyad Oncology announced a partnership with ONO Pharmaceutical to accelerate the development of CYAD-211, an allogeneic CAR-T cell product for the treatment of multiple myeloma. In summary, Celyad Oncology has not only a unique business model but also promising product candidates and technologies that have the potential to revolutionize the treatment of cancer. With a strong pipeline and targeted clinical development, Celyad Oncology is well positioned to continue its success in the future. Celyad Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Celyad Oncology's Liabilities

Celyad Oncology's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Celyad Oncology's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Celyad Oncology's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Celyad Oncology's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Celyad Oncology’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Celyad Oncology Stock

What is the level of liabilities of Celyad Oncology this year?

Celyad Oncology has a debt balance of 9.98 M EUR this year.

What were the liabilities of Celyad Oncology compared to the previous year?

The liabilities of Celyad Oncology have increased by -35.2% dropped compared to the previous year.

What are the consequences of high debt for investors of Celyad Oncology?

High liabilities can pose a risk for investors of Celyad Oncology, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Celyad Oncology?

Low liabilities mean that Celyad Oncology has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Celyad Oncology affect the company?

An increase in liabilities of Celyad Oncology can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Celyad Oncology affect the company?

A decrease in the liabilities of Celyad Oncology can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Celyad Oncology?

Some factors that can influence the liabilities of Celyad Oncology include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Celyad Oncology so important for investors?

The liabilities of Celyad Oncology are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Celyad Oncology take to modify the liabilities?

To change its liabilities, Celyad Oncology can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Celyad Oncology pay?

Over the past 12 months, Celyad Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celyad Oncology is expected to pay a dividend of 0 EUR.

What is the dividend yield of Celyad Oncology?

The current dividend yield of Celyad Oncology is .

When does Celyad Oncology pay dividends?

Celyad Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celyad Oncology?

Celyad Oncology paid dividends every year for the past 0 years.

What is the dividend of Celyad Oncology?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celyad Oncology located?

Celyad Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celyad Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celyad Oncology from 7/1/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.

When did Celyad Oncology pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of Celyad Oncology in the year 2023?

In the year 2023, Celyad Oncology distributed 0 EUR as dividends.

In which currency does Celyad Oncology pay out the dividend?

The dividends of Celyad Oncology are distributed in EUR.